Clinical Trials Update
Hello members,
Nivolumab neoadjuvant/adjuvant clinical trial
The CA209-7FL neoadjuvant/adjuvant
breast cancer trial continues to be open to recruitment, running in South Australia, New South Wales and Victoria for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage
breast cancer. Bristol Myers Squibb will be implementing a digital
advertising campaign expected to launch in October/November 2021. This will
target both health professionals and patients. More information on the trial can be found here.
EMBRACE Phase II Olaparib clinical trial
EMBRACE is a Phase II clinical trial of the PARP inhibitor, Olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Patients with metastatic triple negative breast cancer (TNBC) or relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) after first line/adjuvant therapy who have an eligible tumour molecular analysis result are suitable for the trial. There are 11 sites open in Australia in NSW, QLD, VIC, SA and WA. More information on the trial can be found here or by emailing embrace.study@sydney.edu.au
We encourage members to talk with their treatment team in the first instance about any clinical trials.
